Monoclonal antibody
Dacetuzumab (also known as SGN-40 or huS2C6 ) is a humanized monoclonal antibody [1] being developed for the treatment of CD40 -positive cancers like non-Hodgkin's lymphoma [2] and hematological malignancies .[3]
This drug was developed by Seattle Genetics , Inc.
References
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab , American Medical Association .
^ Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. (September 2009). "Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma" . Journal of Clinical Oncology . 27 (26): 4371–7. doi :10.1200/JCO.2008.21.3017 . PMID 19636010 .
^ Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ (June 2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current Opinion in Investigational Drugs . 10 (6): 579–87. PMID 19513947 .